Literature DB >> 3700650

Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease.

S S Kang, P W Wong, H Y Cook, M Norusis, J V Messer.   

Abstract

The development of atherosclerotic changes and thromboembolism are common features in homocystinurics. Hence, we postulate a positive correlation between the level of homocyst(e)ine in the blood and the occurrence of coronary artery disease. Homocysteine is found either as free homocystine, cysteine-homocysteine mixed disulfide, or protein-bound homocyst(e)ine. In nonhomocystinuric subjects, most homocysteine molecules are detectable in the protein-bound form. Thus, protein-bound homocyst(e)ine in stored plasma which reflected total plasma homocyst(e)ine was determined in 241 patients with coronary artery disease (173 males and 68 females). The mean +/- SD total plasma homocyst(e)ine was 5.41 +/- 1.62 nmol/ml in male patients, 4.37 +/- 1.09 nmol/ml in male controls, 5.66 +/- 1.93 nmol/ml in female patients, and 4.16 +/- 1.62 nmol/ml in female controls. The differences between the patients with coronary artery disease and the controls were statistically significant (P less than 0.0005).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700650      PMCID: PMC424549          DOI: 10.1172/JCI112461

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  The pathogenesis of coronary artery disease. A possible role for methionine metabolism.

Authors:  D E Wilcken; B Wilcken
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

2.  Detection of heterozygotes for homocystinuria. Study of sulphur-containing amino acids in plasma and urine after L-methionine loading.

Authors:  I B Sardharwalla; B Fowler; A J Robins; G M Komrower
Journal:  Arch Dis Child       Date:  1974-07       Impact factor: 3.791

3.  Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.

Authors:  K S McCully
Journal:  Am J Pathol       Date:  1969-07       Impact factor: 4.307

4.  The effect of D-penicillamine on protein-bound homocyst(e)ine in homocystinurics.

Authors:  S S Kang; P W Wong; K Curley
Journal:  Pediatr Res       Date:  1982-05       Impact factor: 3.756

5.  Homocysteine thiolactone and experimental homocysteinemia.

Authors:  N P Dudman; D E Wilcken
Journal:  Biochem Med       Date:  1982-04

6.  Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.

Authors:  L A Harker; R Ross; S J Slichter; C R Scott
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

7.  Accumulation of homocyst(e)ine in vitamin B-6 deficiency: a model for the study of cystathionine beta-synthase deficiency.

Authors:  L A Smolin; N J Benevenga
Journal:  J Nutr       Date:  1982-07       Impact factor: 4.798

8.  A study of cardiovascular risk in heterozygotes for homocystinuria.

Authors:  S H Mudd; R Havlik; H L Levy; V A McKusick; M Feinleib
Journal:  Am J Hum Genet       Date:  1981-11       Impact factor: 11.025

9.  PATHOLOGICAL FINDINGS IN HOMOCYSTINURIA.

Authors:  J B GIBSON; N A CARSON; D W NEILL
Journal:  J Clin Pathol       Date:  1964-07       Impact factor: 3.411

10.  Protein-bound homocyst(e)ine in normal subjects and in patients with homocystinuria.

Authors:  S S Kang; P W Wong; N Becker
Journal:  Pediatr Res       Date:  1979-10       Impact factor: 3.756

View more
  21 in total

1.  The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease.

Authors:  J B Ubbink; W J Vermaak; J M Bennett; P J Becker; D A van Staden; S Bissbort
Journal:  Klin Wochenschr       Date:  1991-08-16

Review 2.  Sex-related differences in oxidative stress and neurodegeneration.

Authors:  Mavis A Tenkorang; Brina Snyder; Rebecca L Cunningham
Journal:  Steroids       Date:  2017-12-20       Impact factor: 2.668

Review 3.  Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature.

Authors:  B V Taylor; G Y Oudit; M Evans
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

4.  Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.

Authors:  G L Booth; E E Wang
Journal:  CMAJ       Date:  2000-07-11       Impact factor: 8.262

Review 5.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

6.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.

Authors:  S S Kang; J Zhou; P W Wong; J Kowalisyn; G Strokosch
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

7.  Hyperhomocysteinaemia: a risk factor for extracranial carotid artery atherosclerosis.

Authors:  R Clarke; D Fitzgerald; C O'Brien; C O'Farrell; G Roche; R A Parker; I Graham
Journal:  Ir J Med Sci       Date:  1992-03       Impact factor: 1.568

8.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen.

Authors:  J S Stamler; J A Osborne; O Jaraki; L E Rabbani; M Mullins; D Singel; J Loscalzo
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  The role of free radicals as mediators of endothelial cell injury in hyperhomocysteinemia.

Authors:  R Clarke; E Naughten; S Cahalane; K O Sullivan; P Mathias; T McCall; I Graham
Journal:  Ir J Med Sci       Date:  1992-09       Impact factor: 1.568

10.  The C677 mutation in methylene tetrahydrofolate reductase gene: correlation with uric acid and cardiovascular risk factors in elderly Korean men.

Authors:  Young Seoub Hong; Myeong Jin Lee; Kyeong Hee Kim; Sang Hwa Lee; Yong Hwan Lee; Byoung Gwon Kim; Baekgeun Jeong; Hyeong Ryeol Yoon; Hisahide Nishio; Joon Youn Kim
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.